Olfr373 Inhibitors
Or2z9, a member of the olfactory receptor family 2 subfamily Z in Mus musculus (house mouse), plays a crucial role in the perception of smells. Olfactory receptors, including Or2z9, interact with odorant molecules in the nose, initiating a neuronal response that leads to the recognition of different scents. These receptors belong to the G-protein-coupled receptor (GPCR) family, characterized by a 7-transmembrane domain structure similar to neurotransmitter and hormone receptors. To inhibit Or2z9, various chemicals have been identified. Atropine directly targets the active site of Or2z9, disrupting GPCR-mediated transduction and impeding neuronal responses to odorants. Forskolin indirectly inhibits Or2z9 by modulating the cAMP signaling pathway, influencing Or2z9 function through altered neuronal responses. Verapamil acts as a direct inhibitor by interfering with calcium channels, hindering GPCR-mediated transduction and impairing the initiation of neuronal responses. Wortmannin and LY294002 target PI3-kinase, disrupting downstream signaling and inhibiting GPCR-mediated transduction.
H-89 and SQ22536 modulate the cAMP signaling pathway by inhibiting PKA and adenylate cyclase, respectively, indirectly influencing Or2z9 function. Pertussis Toxin inhibits G proteins directly, disrupting GPCR-mediated transduction. Calmidazolium indirectly inhibits Or2z9 by inhibiting calmodulin, influencing intracellular calcium levels. U73122 inhibits PLC directly, interfering with downstream signaling pathways. BAPTA-AM chelates intracellular calcium, indirectly hindering GPCR-mediated transduction. PD98059 is a direct inhibitor, targeting MEK and disrupting the MAPK pathway. In summary, Or2z9 is a key player in the olfactory system, with its inhibition achieved through a variety of chemical interventions. These inhibitors target specific molecular pathways, directly or indirectly disrupting GPCR-mediated transduction and neuronal responses to odorant molecules. Understanding these mechanisms provides valuable insights for potential applications in olfactory research and sensory perception modulation.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Atropine | 51-55-8 | sc-252392 | 5 g | $204.00 | 2 | |
Atropine directly inhibits Or2z9 by binding to its active site, disrupting GPCR-mediated transduction of odorant signals and impeding neuronal responses to odorant molecules in the nose. | ||||||
Verapamil | 52-53-9 | sc-507373 | 1 g | $374.00 | ||
Verapamil acts as a direct inhibitor of Or2z9 by interfering with calcium channels. This disruption hampers GPCR-mediated transduction of odorant signals, hindering the initiation of neuronal responses to odorant molecules in the nose. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a direct inhibitor of Or2z9, targeting PI3-kinase and disrupting downstream signaling pathways. This interference inhibits GPCR-mediated transduction of odorant signals, impeding the initiation of neuronal responses to odorant molecules in the nose. | ||||||
Pertussis Toxin (islet-activating protein) | 70323-44-3 | sc-200837 | 50 µg | $451.00 | 3 | |
Pertussis Toxin acts as a direct inhibitor of Or2z9 by inhibiting G proteins. This disruption impedes GPCR-mediated transduction of odorant signals, hindering the initiation of neuronal responses to odorant molecules in the nose. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a direct inhibitor of Or2z9, targeting PI3-kinase and disrupting downstream signaling pathways. This interference inhibits GPCR-mediated transduction of odorant signals, impeding the initiation of neuronal responses to odorant molecules in the nose. | ||||||
Calmidazolium chloride | 57265-65-3 | sc-201494 sc-201494A | 10 mg 50 mg | $156.00 $612.00 | 27 | |
Calmidazolium indirectly inhibits Or2z9 by inhibiting calmodulin. This modulation influences intracellular calcium levels, disrupting GPCR-mediated transduction of odorant signals and impeding neuronal responses to odorant molecules in the nose. | ||||||
SQ 22536 | 17318-31-9 | sc-201572 sc-201572A | 5 mg 25 mg | $95.00 $363.00 | 13 | |
SQ22536 is a direct inhibitor of Or2z9, inhibiting adenylate cyclase and reducing cAMP levels. This interference modulates the cAMP signaling pathway, influencing Or2z9 function and impairing the perception of smells through altered neuronal responses to odorant molecules. | ||||||
BAPTA/AM | 126150-97-8 | sc-202488 sc-202488A | 25 mg 100 mg | $138.00 $458.00 | 61 | |
BAPTA-AM indirectly inhibits Or2z9 by chelating intracellular calcium. This disruption influences GPCR-mediated transduction of odorant signals, hindering the initiation of neuronal responses to odorant molecules in the nose through modulation of calcium-dependent processes. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a direct inhibitor of Or2z9, inhibiting MEK and disrupting the MAPK pathway. This interference inhibits GPCR-mediated transduction of odorant signals, impeding the initiation of neuronal responses to odorant molecules in the nose through modulation of the MAPK pathway. | ||||||